Skip to main content
Top
Published in: Obesity Surgery 9/2018

01-09-2018 | Original Contributions

Sleeve Gastrectomy in Morbidly Obese HIV Patients: Focus on Anti-retroviral Treatment Absorption After Surgery

Authors: Chloé Amouyal, Marion Buyse, Lea Lucas-Martini, Déborah Hirt, Laurent Genser, Adriana Torcivia, Jean-Luc Bouillot, Jean-Michel Oppert, Judith Aron-Wisnewsky

Published in: Obesity Surgery | Issue 9/2018

Login to get access

Abstract

Context

Anti-retroviral therapy (ART) dramatically reduced AIDS development, thus enabling patients to live as long as the general population. New challenges have emerged particularly cardiometabolic diseases and weight gain, with some HIV patients seeking bariatric surgery (BS). However, BS outcomes during HIV remain poorly described, with scarce data on ART pharmacokinetic post-BS.

Objective

Describing sleeve gastrectomy (SG) results in HIV patients in terms of ART pharmacokinetic, HIV control, weight loss, and metabolic outcomes.

Design, Setting, and Patients

Prospective study of HIV patients undergoing SG in a referral academic center, with at least 6 months follow-up.

Main Outcome Measure

Clinical and biological parameters, HIV medical history, and ART pharmacokinetics were gathered before and post-SG.

Results

Seventeen patients (mean BMI = 44.2 ± 5.7 kg m−2) and major obesity-related diseases (47% type-2 diabetes, 64% obstructive sleep apnea, 70% hypertension) underwent SG during a mean 2 years of follow-up. They displayed an average of 20% reduction of initial BMI and improved body composition, similarly to obese non-HIV patients. SG improved metabolic status. All patients had undetectable viral load before BS. Upon HIV follow-up, 12 patients had undetectable viral load with correct ART kinetic parameters (3 and 6 months); 4 displayed detectable viral load along with significant decrease in raltegravir and atazanavir treatment exposure, leading to ART change with subsequent undetectable viral load; and 1 had persistent detectable viral load despite ART change.

Conclusions

SG seems effective and safe in obese HIV patients. However, ART treatment should be monitored post-SG to control HIV infection. We suggest that some ART should be adapted before SG conjoints with infectious disease specialists.
Appendix
Available only for authorised users
Literature
1.
go back to reference Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet Lond Engl. 2008;372:293–9.CrossRef Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet Lond Engl. 2008;372:293–9.CrossRef
2.
go back to reference Lakey W, Yang L-Y, Yancy W, et al. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retrovir. 2013;29:435–40.CrossRef Lakey W, Yang L-Y, Yancy W, et al. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retrovir. 2013;29:435–40.CrossRef
3.
go back to reference Crum-Cianflone N, Roediger MP, Eberly L, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One. 2010;5:e10106.CrossRef Crum-Cianflone N, Roediger MP, Eberly L, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One. 2010;5:e10106.CrossRef
4.
go back to reference Nsagha DS, Assob JCN, Njunda AL, et al. Risk factors of cardiovascular diseases in HIV/AIDS patients on HAART. Open AIDS J. 2015;9:51–9.CrossRef Nsagha DS, Assob JCN, Njunda AL, et al. Risk factors of cardiovascular diseases in HIV/AIDS patients on HAART. Open AIDS J. 2015;9:51–9.CrossRef
5.
go back to reference Pourcher G, Costagliola D, Martinez V. Obesity in HIV-infected patients in France: prevalence and surgical treatment options. J Visc Surg. 2015;152:33–7.CrossRef Pourcher G, Costagliola D, Martinez V. Obesity in HIV-infected patients in France: prevalence and surgical treatment options. J Visc Surg. 2015;152:33–7.CrossRef
6.
go back to reference Angrisani L, Santonicola A, Iovino P, et al. Bariatric surgery and endoluminal procedures: IFSO worldwide survey 2014. Obes Surg. 2017;27:2279–89.CrossRef Angrisani L, Santonicola A, Iovino P, et al. Bariatric surgery and endoluminal procedures: IFSO worldwide survey 2014. Obes Surg. 2017;27:2279–89.CrossRef
7.
go back to reference Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA J Am Med Assoc. 2012;307:56–65.CrossRef Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA J Am Med Assoc. 2012;307:56–65.CrossRef
8.
go back to reference Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.CrossRef Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.CrossRef
9.
go back to reference Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32:2133–5.CrossRef Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32:2133–5.CrossRef
10.
go back to reference Aron-Wisnewsky J, Sokolovska N, Liu Y, et al. The advanced-DiaRem score improves prediction of diabetes remission 1 year post-roux-en-Y gastric bypass. Diabetologia. 2017;60:1892–902.CrossRef Aron-Wisnewsky J, Sokolovska N, Liu Y, et al. The advanced-DiaRem score improves prediction of diabetes remission 1 year post-roux-en-Y gastric bypass. Diabetologia. 2017;60:1892–902.CrossRef
11.
go back to reference Reges O, Greenland P, Dicker D, et al. Association of Bariatric Surgery Using Laparoscopic Banding, roux-en-Y gastric bypass, or laparoscopic sleeve gastrectomy vs usual care obesity management with all-cause mortality. JAMA. 2018;319:279–90.CrossRef Reges O, Greenland P, Dicker D, et al. Association of Bariatric Surgery Using Laparoscopic Banding, roux-en-Y gastric bypass, or laparoscopic sleeve gastrectomy vs usual care obesity management with all-cause mortality. JAMA. 2018;319:279–90.CrossRef
12.
go back to reference Zellmer JD, Mathiason MA, Kallies KJ, et al. Is laparoscopic sleeve gastrectomy a lower risk bariatric procedure compared with laparoscopic Roux-en-Y gastric bypass? A meta-analysis. Am J Surg. 2014;208:903–10. discussion 909-910CrossRef Zellmer JD, Mathiason MA, Kallies KJ, et al. Is laparoscopic sleeve gastrectomy a lower risk bariatric procedure compared with laparoscopic Roux-en-Y gastric bypass? A meta-analysis. Am J Surg. 2014;208:903–10. discussion 909-910CrossRef
13.
go back to reference Pourcher G, Peytavin G, Schneider L, et al. Bariatric surgery in HIV patients: experience of an obesity reference center in France. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2017;13:1990–6.CrossRef Pourcher G, Peytavin G, Schneider L, et al. Bariatric surgery in HIV patients: experience of an obesity reference center in France. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2017;13:1990–6.CrossRef
14.
go back to reference Sharma G, Strong AT, Boules M, Tu C, Szomstein S, Rosenthal R, et al. Comparative outcomes of bariatric surgery in patients with and without human immunodeficiency virus. Obes Surg 2017;28:1070–79.CrossRef Sharma G, Strong AT, Boules M, Tu C, Szomstein S, Rosenthal R, et al. Comparative outcomes of bariatric surgery in patients with and without human immunodeficiency virus. Obes Surg 2017;28:1070–79.CrossRef
15.
go back to reference Alfa-Wali M, Seechurn S, Ayodeji O, et al. Outcomes of bariatric surgery in human immunodeficiency virus positive individuals: a single center experience. Minerva Chir. 2016;71:233–8. Alfa-Wali M, Seechurn S, Ayodeji O, et al. Outcomes of bariatric surgery in human immunodeficiency virus positive individuals: a single center experience. Minerva Chir. 2016;71:233–8.
16.
go back to reference Muzard L, Alvarez J-C, Gbedo C, et al. Tenofovir pharmacokinetic after sleeve-gastrectomy in four severely obese patients living with HIV. Obes Res Clin Pract. 2017;11:108–13.CrossRef Muzard L, Alvarez J-C, Gbedo C, et al. Tenofovir pharmacokinetic after sleeve-gastrectomy in four severely obese patients living with HIV. Obes Res Clin Pract. 2017;11:108–13.CrossRef
17.
go back to reference Selke H, Norris S, Osterholzer D, et al. Bariatric surgery outcomes in HIV-infected subjects: a case series. AIDS Patient Care STDs. 2010;24:545–50.CrossRef Selke H, Norris S, Osterholzer D, et al. Bariatric surgery outcomes in HIV-infected subjects: a case series. AIDS Patient Care STDs. 2010;24:545–50.CrossRef
18.
go back to reference Zivich S, Cauterucci M, Allen S, et al. Long-term virologic outcomes following bariatric surgery in patients with HIV. Obes Res Clin Pract. 2015;9:633–5.CrossRef Zivich S, Cauterucci M, Allen S, et al. Long-term virologic outcomes following bariatric surgery in patients with HIV. Obes Res Clin Pract. 2015;9:633–5.CrossRef
19.
go back to reference Panko N, Dunford G, Lutfi R. HIV infection is not a contraindication to laparoscopic sleeve gastrectomy for morbid obesity. Obes Surg. 2018;28:464–8.CrossRef Panko N, Dunford G, Lutfi R. HIV infection is not a contraindication to laparoscopic sleeve gastrectomy for morbid obesity. Obes Surg. 2018;28:464–8.CrossRef
20.
go back to reference Fysekidis M, Cohen R, Bekheit M, et al. Sleeve gastrectomy is a safe and efficient procedure in HIV patients with morbid obesity: a case series with results in weight loss, comorbidity evolution, CD4 count, and viral load. Obes Surg. 2015;25:229–33.CrossRef Fysekidis M, Cohen R, Bekheit M, et al. Sleeve gastrectomy is a safe and efficient procedure in HIV patients with morbid obesity: a case series with results in weight loss, comorbidity evolution, CD4 count, and viral load. Obes Surg. 2015;25:229–33.CrossRef
21.
go back to reference Flancbaum L, Drake V, Colarusso T, et al. Initial experience with bariatric surgery in asymptomatic human immunodeficiency virus-infected patients. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2005;1:73–6.CrossRef Flancbaum L, Drake V, Colarusso T, et al. Initial experience with bariatric surgery in asymptomatic human immunodeficiency virus-infected patients. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2005;1:73–6.CrossRef
22.
go back to reference Eddy F, Elvin S, Sanmani L. Bariatric surgery: an HIV-positive patient’s successful journey. Int J STD AIDS 2015;27:70–1.CrossRef Eddy F, Elvin S, Sanmani L. Bariatric surgery: an HIV-positive patient’s successful journey. Int J STD AIDS 2015;27:70–1.CrossRef
23.
go back to reference Fazylov R, Soto E, Merola S. Laparoscopic gastric bypass surgery in human immunodeficiency virus-infected patients. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2007;3:637–9.CrossRef Fazylov R, Soto E, Merola S. Laparoscopic gastric bypass surgery in human immunodeficiency virus-infected patients. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2007;3:637–9.CrossRef
24.
go back to reference MacBrayne CE, Blum JD, Kiser JJ. Tenofovir, emtricitabine, and darunavir/ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery. Ann Pharmacother. 2014;48:816–9.CrossRef MacBrayne CE, Blum JD, Kiser JJ. Tenofovir, emtricitabine, and darunavir/ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery. Ann Pharmacother. 2014;48:816–9.CrossRef
25.
go back to reference Malone M. Altered drug disposition in obesity and after bariatric surgery. Nutr Clin Pract Off Publ Am Soc Parenter Enter Nutr. 2003;18:131–5. Malone M. Altered drug disposition in obesity and after bariatric surgery. Nutr Clin Pract Off Publ Am Soc Parenter Enter Nutr. 2003;18:131–5.
26.
go back to reference Edwards A, Ensom MHH. Pharmacokinetic effects of bariatric surgery. Ann Pharmacother. 2012;46:130–6.CrossRef Edwards A, Ensom MHH. Pharmacokinetic effects of bariatric surgery. Ann Pharmacother. 2012;46:130–6.CrossRef
27.
go back to reference Verger EO, Aron-Wisnewsky J, Dao MC, Kayser BD, Oppert J-M, Bouillot J-L, et al. Micronutrient and protein deficiencies after gastric bypass and sleeve gastrectomy: a 1-year follow-up. Obes Surg 2015;26:785–96.CrossRef Verger EO, Aron-Wisnewsky J, Dao MC, Kayser BD, Oppert J-M, Bouillot J-L, et al. Micronutrient and protein deficiencies after gastric bypass and sleeve gastrectomy: a 1-year follow-up. Obes Surg 2015;26:785–96.CrossRef
28.
go back to reference Yuen GJ, Lou Y, Bumgarner NF, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother. 2004;48:176–82.CrossRef Yuen GJ, Lou Y, Bumgarner NF, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother. 2004;48:176–82.CrossRef
29.
go back to reference Wang LH, Chittick GE, McDowell JA. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1999;43:1708–15.CrossRef Wang LH, Chittick GE, McDowell JA. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1999;43:1708–15.CrossRef
30.
go back to reference Curran A, Martí R, López RM, et al. Darunavir and ritonavir Total and unbound plasmatic concentrations in HIV-HCV-Coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients. Antimicrob Agents Chemother. 2015;59:6782–90.CrossRef Curran A, Martí R, López RM, et al. Darunavir and ritonavir Total and unbound plasmatic concentrations in HIV-HCV-Coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients. Antimicrob Agents Chemother. 2015;59:6782–90.CrossRef
31.
go back to reference Blum MR, Chittick GE, Begley JA, et al. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol. 2007;47:751–9.CrossRef Blum MR, Chittick GE, Begley JA, et al. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol. 2007;47:751–9.CrossRef
32.
go back to reference Zong J, Chittick GE, Wang LH, et al. Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. J Clin Pharmacol. 2007;47:877–89.CrossRef Zong J, Chittick GE, Wang LH, et al. Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. J Clin Pharmacol. 2007;47:877–89.CrossRef
33.
go back to reference Iwamoto M, Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis Off Publ Infect Dis Soc Am. 2008;47:137–40.CrossRef Iwamoto M, Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis Off Publ Infect Dis Soc Am. 2008;47:137–40.CrossRef
34.
go back to reference von Hentig N, Babacan E, Lennemann T, et al. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother. 2008;62:579–82.CrossRef von Hentig N, Babacan E, Lennemann T, et al. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother. 2008;62:579–82.CrossRef
35.
go back to reference Ofotokun I, Chuck SK, Binongo JN, et al. Lopinavir/ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy. J Clin Pharmacol. 2007;47:970–7.CrossRef Ofotokun I, Chuck SK, Binongo JN, et al. Lopinavir/ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy. J Clin Pharmacol. 2007;47:970–7.CrossRef
36.
go back to reference Sawaya RA, Jaffe J, Friedenberg L, et al. Vitamin, mineral, and drug absorption following bariatric surgery. Curr Drug Metab. 2012;13:1345–55.CrossRef Sawaya RA, Jaffe J, Friedenberg L, et al. Vitamin, mineral, and drug absorption following bariatric surgery. Curr Drug Metab. 2012;13:1345–55.CrossRef
37.
go back to reference Mans E, Serra-Prat M, Palomera E, et al. Sleeve gastrectomy effects on hunger, satiation, and gastrointestinal hormone and motility responses after a liquid meal test. Am J Clin Nutr. 2015;102:540–7.CrossRef Mans E, Serra-Prat M, Palomera E, et al. Sleeve gastrectomy effects on hunger, satiation, and gastrointestinal hormone and motility responses after a liquid meal test. Am J Clin Nutr. 2015;102:540–7.CrossRef
38.
go back to reference Ying VWC, Kim SHH, Khan KJ, et al. Prophylactic PPI help reduce marginal ulcers after gastric bypass surgery: a systematic review and meta-analysis of cohort studies. Surg Endosc. 2015;29:1018–23.CrossRef Ying VWC, Kim SHH, Khan KJ, et al. Prophylactic PPI help reduce marginal ulcers after gastric bypass surgery: a systematic review and meta-analysis of cohort studies. Surg Endosc. 2015;29:1018–23.CrossRef
39.
go back to reference Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49:509–33.CrossRef Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49:509–33.CrossRef
40.
go back to reference Ray JE, Marriott D, Bloch MT, et al. Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol. 2005;60:291–9.CrossRef Ray JE, Marriott D, Bloch MT, et al. Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol. 2005;60:291–9.CrossRef
41.
go back to reference Dybul M, Fauci AS, Bartlett JG, et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep Cent Dis Control. 2002;51:1–55. Dybul M, Fauci AS, Bartlett JG, et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep Cent Dis Control. 2002;51:1–55.
42.
go back to reference Acosta EP, Gerber JG, Adult Pharmacology Committee of the AIDS Clinical Trials Group. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retrovir. 2002;18:825–34.CrossRef Acosta EP, Gerber JG, Adult Pharmacology Committee of the AIDS Clinical Trials Group. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retrovir. 2002;18:825–34.CrossRef
43.
go back to reference Moss DM, Siccardi M, Murphy M, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012;56(6):3020–6.CrossRef Moss DM, Siccardi M, Murphy M, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012;56(6):3020–6.CrossRef
44.
go back to reference Kassir R, Huart E, Tiffet O, et al. Feasibility of bariatric surgery in the HIV-infected patients. Obes Surg. 2017;27:818–9.CrossRef Kassir R, Huart E, Tiffet O, et al. Feasibility of bariatric surgery in the HIV-infected patients. Obes Surg. 2017;27:818–9.CrossRef
45.
go back to reference Soares LR, da Silva DC, Gonsalez CR, et al. Discordance between body mass index and anthropometric measurements among HIV-1-infected patients on antiretroviral therapy and with lipoatrophy/lipohypertrophy syndrome. Rev Inst Med Trop São Paulo. 2015;57:105–10.CrossRef Soares LR, da Silva DC, Gonsalez CR, et al. Discordance between body mass index and anthropometric measurements among HIV-1-infected patients on antiretroviral therapy and with lipoatrophy/lipohypertrophy syndrome. Rev Inst Med Trop São Paulo. 2015;57:105–10.CrossRef
46.
go back to reference Ciangura C, Bouillot J-L, Lloret-Linares C, et al. Dynamics of change in total and regional body composition after gastric bypass in obese patients. Obes Silver Spring Md. 2010;18:760–5.CrossRef Ciangura C, Bouillot J-L, Lloret-Linares C, et al. Dynamics of change in total and regional body composition after gastric bypass in obese patients. Obes Silver Spring Md. 2010;18:760–5.CrossRef
Metadata
Title
Sleeve Gastrectomy in Morbidly Obese HIV Patients: Focus on Anti-retroviral Treatment Absorption After Surgery
Authors
Chloé Amouyal
Marion Buyse
Lea Lucas-Martini
Déborah Hirt
Laurent Genser
Adriana Torcivia
Jean-Luc Bouillot
Jean-Michel Oppert
Judith Aron-Wisnewsky
Publication date
01-09-2018
Publisher
Springer US
Published in
Obesity Surgery / Issue 9/2018
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-018-3308-7

Other articles of this Issue 9/2018

Obesity Surgery 9/2018 Go to the issue